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Abstract
Considerable research efforts are being invested in the development of novel antimicro-
bial therapies effective against the growing number of multi-drug resistant pathogens.
Notably, the combination of different agents is increasingly explored as means to exploit
and improve individual agent actions while minimizing microorganism resistance.
Although there are several databases on antimicrobial agents, scientific literature is the
primary source of information on experimental antimicrobial combination testing. This
work presents a semi-automated database curation workflow that supports the mining of
scientific literature and enables the reconstruction of recently documented antimicrobial
combinations. Currently, the database contains data on antimicrobial combinations that
have been experimentally tested against Pseudomonas aeruginosa, Staphylococcus aur-
eus, Escherichia coli, Listeria monocytogenes and Candida albicans, which are promin-
ent pathogenic organisms and are well-known for their wide and growing resistance to
conventional antimicrobials. Researchers are able to explore the experimental results for
a single organism or across organisms. Likewise, researchers may look into indirect net-
work associations and identify new potential combinations to be tested. The database is
available without charges.
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Introduction
Antimicrobial resistance is currently one of the major
health threats worldwide. Recent statistics from the
Centers of Disease Control and Prevention (CDC) indicate
that, each year, at least 2 million people become infected
with antibiotic-resistant bacteria in the USA and 23 000
people die as a direct result of these infections (http://
www.cdc.gov/drugresistance/). Other reports state over
700 000 deaths per year worldwide (1).
Antimicrobial agents, i.e. antibiotics and similar drugs,
have been so widely overused and misused that the infec-
tious organisms were selectively pressured to develop re-
sistance towards them (2). The main mechanisms of action
of antimicrobials include interference with cell wall synthe-
sis (e.g. beta-lactams), inhibition of protein synthesis (e.g.
tetracyclines), interference with nucleic acid synthesis (e.g.
fluoroquinolones and rifampin), inhibition of a metabolic
pathway (e.g. trimethoprim-sulfamethoxazole), and dis-
ruption of bacterial membrane structure (e.g. polymyxins
and daptomycin) (3). Microorganisms may be intrinsically
resistant to one or more classes of antimicrobial agents, or
may acquire resistance by de novo mutation or via the ac-
quisition of resistance genes from other organisms.
Acquired resistance genes may enable the microorganism
to produce enzymes that destroy the antimicrobial drug, to
express efflux systems that prevent the drug from reaching
its intracellular target, to modify the drug’s target site, or
to produce an alternative metabolic pathway that bypasses
the action of the drug. The number of multi-drug resistant
(MDR) strains and pandrug resistant isolates is growing
continuously and rendering conventional antibiotics less
effective (4, 5).
Clinical and microbiological research is thus devoting
significant attention to the understanding of antimicrobial
resistance phenomena, the discovery of alternative agents
(or mechanisms of action), and the development of new
antimicrobial strategies (6, 7). In this context, antimicro-
bial peptides (AMP) are recognized as a promising anti-
microbial agents that have a broad spectrum of activity
and show low specificity in terms of molecular targets,
which helps lower the chance of microorganisms develop-
ing resistance (8). AMP support antimicrobial action by
aiding cellular processes like cytokine release, chemotaxis,
antigen presentation, angiogenesis and wound healing (9,
10), and are active against biofilms, which are one of the
most concerning mechanisms of microbial resistance and a
major cause of resilient infections, such as biomaterial
related infections and chronic infections (11–13).
Now, alongside the discovery of new antimicrobial
agents, researchers are looking into potentiating the action
of both old and new substances. In particular, one possible
solution is to look for synergic combinations of two or
more antimicrobial agents, which increase the antimicro-
bial spectrum and potentiate the individual efficacy of the
agents, while avoiding antimicrobial resistance and reduc-
ing toxicity and other side effects (6). The challenge resides
in the rational combination of compounds and in finding
the most promising mechanisms of action to treat particu-
lar infections and to overcome specific mechanisms of
resistance.
The huge number of compounds available and the var-
iety of possible combinations is leading to the accumula-
tion of a large and highly diversified volume of
experimental data. Several public databases store informa-
tion on drugs, AMP and other compounds with antimicro-
bial potential, but scientific literature remains as the
primary source of information (14–18). Databases do not
provide enough details on susceptibility testing that may be
used by researchers to evaluate individual and joint anti-
microbial effects.
Within this scope, mining the bibliome for experimen-
tally validated antimicrobial combinations has the poten-
tial to provide researchers insights on existing results and
infer the most promising combinations to be tested next.
Previous works have successfully developed text mining
methods and tools for the reconstruction of pharmacoki-
netic experimental evidence (19), adverse drug-drug inter-
actions (20), and drug-gene and drug-disease interactions
(21, 22), among others. Although the focus of these works
is different, the extraction of experimental evidence of anti-
microbial agent combinations can get inspiration from
these computational workflows and use some of the tools
and resources.
Therefore, this work presents a semi-automated know-
ledge extraction workflow that was developed to allow the
extraction of correlative relationships about the combin-
ation of antimicrobial agents from scientific literature.
This workflow integrates state-of-the-art text mining tech-
nologies and expert manual curation in support of the
compilation of detailed information on antimicrobial com-
binations (involving both drugs and AMP) tested against
major pathogenic bacteria and fungi. Moreover, it resorts
to network representation as means to enable query and
visualization at large scale and help users explore direct
and indirect associations in an easy and comprehensible
manner.
Current, the database contains 1556 combinations, en-
compassing 345 AMP and 282 drugs, tested on P. aeruginosa,
S. aureus, E. coli, L. monocytogenes and C. albicans.
Presently, and to the best knowledge of the authors, no other
database provides information regarding the testing of AMP-
related combinations. This database is publicly available at
http://sing.ei.uvigo.es/antimicrobialCombination/.
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Materials and Methods
This section describes the integrated and semi-automated
data curation workflow developed to reconstruct experimen-
tally validated AMP and drug combinations. This curation
workflow is iterative, i.e. the aim is to keep up with new find-
ings about antimicrobial combinations and therefore, future
versions of the database will likely cover new antimicrobial
agents as well as a broader scope of pathogenic microorgan-
isms. Accordingly, the workflow is designed to enable
domain-specific curation with active lexicon enrichment and
calibration of automatic procedures.
As illustrated in Figure 1, the developed workflow inte-
grates modules for the retrieval of target documents, the
processing, annotation and analysis of their contents, and
the visualization of the combination profiles of antimicro-
bial agents. A prototype of this data curation workflow
was previously implemented for an initial reconstruction
of antimicrobial combinations tested against P. aeruginosa
(23). The lessons learned about how to integrate the auto-
matic and manual processes of curation, and on how to
apply such curation to other organisms and specific anti-
microbials, reflected directly in the architecture of the
workflow presented here.
Next, we detail the main aspects of the current
workflow.
Document retrieval and pre-processing
The NCBI (National Center for Biotechnology
Information) Entrez Utilities Web services are used to ac-
cess the PubMed library, search for potentially relevant
articles and download the publication details, including
the titles and abstracts to be further processed (24).
The aim here is to find scientific literature about the ex-
perimental validation of antimicrobial combinations,
namely combinations involving common, commercial
drugs (e.g. antibiotics, disinfectants) and AMP (natural or
designed). Therefore, the scope of the search is narrowed
to documents whose title or abstract mentions terms that
commonly denote the test of agent combinations (e.g.
‘combination’, ‘synerg*’ or ‘antagon*’, where the ‘*’ is a
wildcard), and experimental methods specific to antimicro-
bial combination susceptibility testing (e.g. ‘checkerboard
assay’ or ‘FBC’). Moreover, the search is organism-centric
(i.e. we specify the organism) as we chose to compile a
meaningful set of documents about a subset of organisms
as opposed to have a set of documents that covers a wide
range of organisms but is not able to provide a decent
understanding on research outcomes for each organism.
Most notably, the database covers studies on P. aeruginosa,
S. aureus, L. monocytogenes, E. coli and C. albicans,
which are major MDR pathogens and attract considerable
attention from the research community.
Basic text processing steps, namely tokenization, stem-
ming, and stop word removal, required by some of the en-
tity recognition and document assessment algorithms, were
implemented using Apache Lucene (http://lucene.apache.
org/). These procedures are applied at document arrival
and after combining title and abstract into a single text.
Entity recognition
Named entity recognition methods are used to identify
mentions of critical entities, notably antimicrobial agents,
experimental methods specific to antimicrobial susceptibil-
ity testing, and organisms. These annotations are used to
index document contents and reconstruct meaningful rela-
tions. Moreover, the number of unique drug and AMP
mentions per abstract is also used as a classification feature
by the document relevance model.
The automatic recognition of antibiotic and AMP text-
ual mentions is accomplished with the help of in-house
built dictionaries.
We have downloaded the drug lexicon from DrugBank
and includes both FDA-approved drugs and experimental
drugs (14). The peptide lexicon was downloaded from
CAMP (17) and LAMP (25), focusing on peptides ex-
tracted from natural sources. Additional lexicon on poten-
tially bioactive compounds and substances (e.g. enzymes,
natural products and synthetic products) was retrieved
from the databases CHEBI (18), PubChem (26), CHEMBL
(27) and the protein catalogue of Uniprot (28). All this in-
formation was parsed and stored in a custom database and
contains a total of 284 337 entries, including 280 503
drugs and 3749 drug-like bioactive compounds and pep-
tides. The average length of common entity names is 30.27
and the average number of synonyms is 11.
The dictionary used in entity recognition represents a
subset of these contents. Contents were filtered according
to the role, action or classification associated to the agents
by database curators. Our experts explored database-
specific classification/annotation and provided a list of the
filtering terms. The dictionary contains a total of 36 259
entries, including 32 772 drugs and 3487 drug-like bio-
active compounds and peptides. Further information about
the extraction, parsing and filtering steps of this data
workflow can be found in Supplementary Materials.
Similarly, a dictionary-based approach is used to detect
textual mentions of the methods used to test the efficacy of
antimicrobial agent combinations, and the description of
combination effects, such as synergies and antagonisms.
This dictionary was built in-house in collaboration with
field experts (29, 30) (see Supplementary Material 2).
Database, Vol. 2016, Article ID baw143 Page 3 of 16
Finally, the state-of-the-art NER taggers LINNAEUS (31)
and ABNER (32) are used to identify species and drug tar-
gets, respectively.
Document relevance assessment
The P. aeruginosa, S. aureus and E. coli documents
retrieved from PubMed were manually labelled by experts
to train of the relevance assessment method. Initially, the
title and abstract texts of these documents are stemmed
with the Porter algorithm (33), filtering out short words
with two or fewer letters, and removing common stop
words. The predictive ability of remaining words is then
examined. The probability pTP(w) that a word w appears
in a positive abstract (i.e. relevant abstract) is calculated as
the ratio of the number of positive abstracts containing w
over the total number of positive abstracts. Similarly, the
probability pTN(w) that a word w appears in a negative ab-
stract (i.e. irrelevant abstract) is calculated as the ratio of
the number of negative abstracts containing w over the
total number of negative abstracts. Then, words are ranked
according to the score:
SðwÞ ¼ pTP wð Þ  pTNðwÞj j
Words with the highest score S tend to be associated
with either positive or negative abstracts and thus, are
assumed to be good features for classification.
The predictive ability of pairs of words immediately ad-
jacent in the text and of unique pairs of words that
co-occur in the documents is also considered. These two
additional feature sets are obtained from the stemmed
word features in the first set. The predictive ability of such
pairs of words (wi, wj) is calculated as the probability of
appearing in a positive or negative abstract, pTP(wi, wj)
and pTN(wi, wj), respectively.
In addition to unigrams, bigrams and co-occurring
words features, the predictive model also takes into ac-
count the number of unique drug and AMP mentions per
abstract a, nd(a) and namp(a), respectively (see details in
‘Entity recognition’ section).
Figure 1. Schema of the integrated and semi-automated curation workflow. The curation process starts with the automatic search and retrieval of
PubMed records. Text mining methods support the annotation of relevant entities (antimicrobial agents, methods for antimicrobial susceptibility test-
ing, type of agent combination, and organisms) and the assessment of document relevance. Articles deemed relevant are further curated manually
by experts that revise automatic annotations and look into additional information about the types of combinations and other relevant details of the
experiments. Articles describing previously uncharacterized AMP combinations are added to the network.
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The information from the various textual and entity
count features is integrated in a variable trigonometric
threshold linear classifier (34–36). Typically, this classifier
defines a decision surface, i.e. a pTP/pTN plane, where those
feature terms with better predictive ability are close to ei-
ther one of the axes. Any feature term w is a vector on this
plane, and therefore term relevance to each of the classes
can be measured with the traditional trigonometric meas-
ures of the angle a, of this vector with the pTP axis. That is,
the cos(a) is a measure of how strongly terms are exclu-
sively associated with positive abstracts, and sin(a) is a
measure of how strongly terms are exclusive of negative
abstracts. So, for every abstract a, relevance is assessed on
the basis of the sum of the contribution of all feature terms
for a positive (P) and negative (N) decision:
PðdÞ ¼Pw2d cos ðaðwÞÞ ¼Pw2d pPðwÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p2PðwÞ þ p2NðwÞ
q
NðdÞ ¼Pw2d sin ðaðwÞÞ ¼Pw2d pNðwÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p2PðwÞ þ p2NðwÞ
q
The decision of whether a given abstract a is relevant
(positive) or not (negative) is computed as follows:
ndðaÞ þ nampðaÞ
b
 
  PðaÞ
NðaÞ þ k
 
here k is a constant threshold for deciding whether an ab-
stract is positive or negative. This threshold is subsequently
adjusted for each abstract a with the factor nd að ÞþnampðaÞb
 
,
where b is a constant, and nd að Þ þ nampðaÞ is the number
of unique drugs and AMP in the abstract as described in
the feature selection subsection.
The values of k and b are optimized by performing k-
fold tests (k ¼ 4) on the training data. Specifically, we
swept the following parameter range: k 2 [0.25, 10] and b
2 [1, 50], in steps of Dk ¼ 0.25 and Db ¼ 2. For each (k; b)
pair, we compute the mean of the F-score and accuracy
measures for each of the four k-fold tests. We rank classi-
fiers according to the mean value of F-score (rF) and accur-
acy (rA) and then, we rank all classifiers tested according to
the rank product, i.e. R ¼ rF  rA. Supplementary
Materials details this evaluation.
Expert manual curation
The Markyt annotation tool (37) supports document man-
ual curation and feeds several modules of the developed
workflow as follows: provides insights on possible diction-
ary updates to the entity recognition module; makes avail-
able information on manual relevance assessment to
enable the update of the automatic relevance assessment
model; and, outputs the information necessary to recon-
struct the combination networks, i.e. antimicrobial agents,
the antimicrobial combinations and further details pro-
vided by the annotated textual evidences.
Manual curation guidelines address both relevance as-
sessment and semantic annotation. A document is labelled
as relevant if it describes the experimental testing of one or
more antimicrobial combinations and at least one of these
combinations involves an AMP. Moreover, curators were
instructed to exclude non English documents and reviews.
The biological concepts considered important for the re-
construction of the AMP-drug combination networks are
described in Table 1. Basically, interest is set on the identi-
fication of the antimicrobial agents tested, the infectious
organism(s) targeted (including whenever possible the
strain), the mode of growth of the microbial culture, and
the antimicrobial susceptibility method(s) used.
From our experience, curators are usually able to check
document relevance by analysing the abstract of the art-
icles. However, it is often the case that full-text examin-
ation is required to confirm relevance and to extract some
of the information of interest, notably details on the experi-
mental procedures. In each iteration, experts revise the
documents automatically labelled as relevant by the pre-
dictive model and a fraction of the documents labelled as ir-
relevant (with better ranking score). As such, we may
identify deficiencies in automatic entity recognition (namely
in dictionary coverage), and the necessity to recalibrate the
k and b thresholds of the predictive assessment model.
For the automatic annotation to be considered accurate,
it should correctly identify the type of the entity and mark
an acceptable fragment of the corresponding textual men-
tion. Inconsistencies, glitches, misses, and interpretation
issues are amended by the experts and duly documented
for future improvement of the workflow (namely, to im-
prove the vocabulary and matching rules supporting auto-
matic annotation, and the priority given to NER tool
outputs).
Abstracts mainly contain a summary of the obtained re-
sults, and in particular, they typically describe only the
best performing combinations. Therefore, the full-texts of
the documents deemed relevant are always manually cura-
ted in order to annotate all the combinations tested. The
curators manually relate the antimicrobial agents forming
each combination and classify the combinations based on
the described effects. Four different types of combinations
are considered: ‘synergic’, i.e. the combined action is super-
ior to the sum of the isolated actions; ‘additive’, i.e. the
combined action is equal to the sum of the isolated actions;
‘indifferent’, i.e. the combined action is equal to the action
of the most active single agent; and, ‘antagonic’, i.e. the
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combined action is inferior to the action of the most active
single agent. In some cases, other categories named ‘addi-
tive/indifferent’ or ‘synergic/additive’ are used to denote
that results were not conclusive.
Although curating the full-texts, curators have to ana-
lyse the materials and methods and the results sections in
order to understand the methodology applied in the study
and the results obtained for each combination. If the typ-
ical methodologies for testing combinations in vitro are
applied (e.g. checkerboard assay, fractional inhibition con-
centration (FIC) and/or FBC determination, and time-kill
assay), the annotation of the results is easier, because the
conclusions are usually quantifiable. For example, synergy
can be indicated by FIC or FBC  0.5 or by log decrease 
2 on viable cells when comparing the action of the combin-
ations with the action of the most active single agent (38).
However, the interpretation of results obtained by less
standard methodologies may be more challenging.
Likewise, many documents do not describe textually the
results of all the tested combinations, and curators often
need to analyse data shown in graphs or tables to be able
to document all combinations and their results properly.
This is particularly true for less successful combinations,
i.e. non synergic combinations.
Network visualization and search
The database of antimicrobial combinations is publicly ac-
cessible through a Web-based interface. This interface
allows users to formulate queries at different levels of spe-
cificity, e.g. filtering the antimicrobial combinations by or-
ganism, antimicrobial agent and combination effect.
Specifically, a Cytoscape Web (39) based interactive net-
work browser supports user customized database queries
and the visualization of network relationships between
antimicrobial agents.
Network representation offers an intuitive and visually
appealing means to observe and navigate a potentially
large number of relationships. Furthermore, the analysis of
network topology provides descriptive statistics about the
agents and types of combinations matching the user query
and enables the inference of indirect associations.
Network nodes denote antimicrobial agents and edges
identify experimentally validated combinations among
agents. Accordingly, node records describe the antimicro-
bial agents and cross-link with primary chemical data-
bases, whereas edge records detail information of the
experimental results (i.e. type of combination, strain, mode
of growth and experimental methods). Moreover, both
nodes and edges are linked to the supporting literature.
The size and the colour of the node are dependent on its de-
gree, i.e. the number of antimicrobial combinations in which
the agent participates, and the width of the edge indicates the
number of documents that describe the combination.
Additionally, the shortest path algorithm enables the identifica-
tion of indirect relations between antimicrobial agents, i.e. the
identification of combinations not yet tested, but apparently
reasonably possible considering the documented results.
Users are able to navigate through tested combinations
and identify which agents have already been tested to-
gether and those that have not been tested together but are
recurrently tested with similar agents. Also, users may look
into specific types of combinations, e.g. synergic effects, as
well as look for combinations tested against a particular
target or across multiple organisms.
Besides the Cytoscape Web browser, this Web interface
utilizes consolidated Web technologies. PHP programming
language (version 5.5) and the MySQL database engine (ver-
sion 5.1.73) support the server side operations. HTML5
(http://www.w3.org/TR/html5/) and CSS3 technologies
(http://www.css3.info/) provide for common interface fea-
tures. Finally, Ajax and JQuery (http://jquery.com/) technol-
ogies help in user-system interaction, such as query facets.
Results and discussion
Database statistics
Currently, the database contains primarily data on anti-
microbial combinations that have been experimentally
Table 1. Relevant entities to the reconstruction of antimicrobial combination networks
Named entity Annotation procedure Description
Antimicrobial agent Semi-automatic Commercial drugs, antibiotics, antifungals, AMP (natural and designed),
enzymes, disinfectants
Organism Semi-automatic Pathogenic bacteria and fungi
Strain Manual Reference strain, isolated strain (clinical isolate, food isolate)
Mode of growth Manual Planktonic, biofilm, in vivo
Experimental tests Semi-automatic Checkerboard assay and/or FIC and/or FBC determination
Time-kill assay
Other (e.g. MIC, MBC, bacterial counts, cell viability, etc)
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tested against P. aeruginosa, S. aureus, E. coli, L. monocy-
togenes and C. albicans, which are prominent pathogenic
organisms and are well-known for their wide and growing
resistance to conventional antimicrobials.
The number of documents retrieved from the literature
was far greater for the bacteria S. aureus and E. coli (more
than a thousand documents each) than for P. aeruginosa,
L. monocytogenes and C. albicans (a few hundred docu-
ments each) (Table 2). Interestingly, this difference is less
noticeable when considering the number of documents
deemed relevant. For example, the number of relevant
documents for E. coli is approximately 1/20 of the number
of retrieved documents and, in contrast, this same propor-
tion is 1/5 for L. monocytogenes. Considering that S. aur-
eus and E. coli are highly studied pathogens, it was
expected that PubMed queries could yield large result sets
with a considerable number of false positives. It was often
the case that abstracts contained relevant entities to the tar-
get domain, but expert manual curation (sometimes resort-
ing to full-text examination) determined that the textual
context of these entities was not of interest. For example,
the document with PMID: 18326181 refers to potentially
relevant keywords, such as ‘nisin’, ‘combination effects’
and ‘E. coli’. However, experts determined that the AMP
nisin was not tested in combination with any other drug/
AMP against E. coli.
The analysis of the annotated combinations provided
some insights about the type of studies that are being per-
formed and which AMP and drugs (and mechanisms of ac-
tion) are being combined. As shown in Table 3, studies
follow a similar path regardless the organism: AMP are in
their majority combined with antibiotics and antifungals;
combinations of only AMP represent only 1–19% of the
total combinations tested. The only exception to this scen-
ario is L. monocytogenes, for which no antibiotic or anti-
fungal was used, and AMP were mostly combined with
other agents such as plant extracts and various chemicals
(i.e. acids, alcohols, salts, organic compounds); however,
AMP-AMP combinations still represent a small percentage
(17.86%) of the total number of combinations. The recy-
cling and potentiation of old and current antibiotics with
the aid of other antimicrobials or antimicrobial adjuvants
is one of the current antimicrobial strategies to fight anti-
microbial resistance (6) and can explain these percentages.
Another interesting observation is that AMP combin-
ations are being tested mainly on planktonic cultures (84–
99%) (Table 3). Today, it is well-known that most bacteria
are naturally present in consortia, i.e. a biofilm mode of
growth, and most infections, namely the most resilient, are
related to these microbial consortia (40). Therefore, as it
stands, current studies give limited information about the
effect of the tested combinations in real life conditions and
it would be desirable to have more experimental data on
biofilms.
Finally, one may observe that the experimental methods
most used in these studies are the checkerboard, the FIC
determination and the fractional bactericidal concentration
(FBC) determination (the latest two are usually coupled),
and the majority of the combinations resulted in synergic
outcomes (Table 3). Both findings were somewhat ex-
pected since the referred methods are standard for this type
of combinatorial research and scientific articles often tend
to report only/majorly positive outcomes.
Table 4 presents the top 3 most annotated AMP, drugs
and organism strains. Regarding the most annotated AMP,
it is interesting to note that some of them are tested across
organisms, with a total of seven different AMP out of a
possible 15 AMP (top 3 AMP * 5 different organisms).
Polymyxins, specifically colistin (polymyxin E) and poly-
myxin B, are one of the most annotated AMP groups. Both
AMP groups were present in the top most annotated AMP
for P. aeruginosa, L. monocytogenes and C. albicans.
Polymyxins are mainly active against Gram-negative
pathogens, including very important nosocomial patho-
gens such as E. coli and P. aeruginosa (41). Nevertheless,
colistin was also tested in combinations against the Gram-
positive L. monocytogenes and the yeast C. albicans (Table
4), illustrating that researchers are taking advantage of its
diverse spectrum of activity to tackle a broader set of infec-
tion agents.
Nisin and lactoferricin B are also commonly tested in
three of the five microorganisms. Nisin is the main repre-
sentative of the AMP class of lantibiotics and is commer-
cially available as a food additive. This AMP is known to
Table 2. General statistics about the retrieved and annotated documents per organism
Microorganism Retrieved documents Relevant documents Annotated combinations Download date
P. aeruginosa 574 109 658 June–July (2015)
S. aureus 1078 101 462 June–July (2015)
E. coli 1472 69 283 June–July (2015)
L. monocytogenes 190 34 56 July–August (2015)
C. albicans 373 29 97 September–October (2015)
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be active against major Gram-positive pathogens such as
L. monocytogenes and S. aureus (42), but it is also being
tested against the Gram-negative E. coli (Table 4). On the
other hand, lactoferricin B is a naturally occurring AMP in
mammals with various intracellular targets against bac-
teria, and has well documented action against major
pathogens such as E. coli and S. aureus (43), and now it is
also tested against yeast (Table 4).
Regarding the most combined drugs, traditional antibi-
otics, such as ciprofloxacin, are the most used in the com-
binations tested against P. aeruginosa and S. aureus (Table
4). Likewise, antifungals are commonly integrated in the
combinations tested against C. albicans (Table 4).
However, it is interesting to note that the substance most
combined with AMP in E. coli and L. monocytogenes stud-
ies is NaCl (sodium chloride) (Table 4). Many AMP have
reduced antimicrobial activity in mediums with high ionic
strengths or even at physiological salt concentrations (44).
Therefore, recent combination studies aim to understand
this phenomenon.
Finally, a considerable number of the AMP combin-
ations are tested against clinical isolates (strains isolated
from real-life infections). These strains are the best repre-
sentatives of the resistance encountered on infection scen-
arios and therefore, serve as a more realistic baseline of
comparison with reference strains. In fact, studies usually
cover more clinical isolates than reference strains.
A retrospective analysis of combination studies may
also be interesting to understand existing and prospective
lines of research, notably the increasing interest in investi-
gating antimicrobial agents with alternative mechanisms of
action. In particular, it is noticeable the attention that
AMP are receiving and the growing number of studies test-
ing these agents in combination with conventional com-
pounds and drugs (Figure 2). Most of these studies are
devoted to critical pathogenic organisms such as P. aerugi-
nosa and S. aureus, which have developed severe resistance
mechanisms to most of existing antibiotics. Moreover, one
may observe that although the number of relevant docu-
ments for P. aeruginosa and S. aureus are not far apart, the
number of AMP combinations evaluated is much greater
for P. aeruginosa. This can indicate that the amount of
tested combinations per paper is higher for this bacteria.
Web interface and user interaction
The Web interface supporting the reconstructed antimicro-
bial networks consists of a collection of pages documenting
the motivation and goals of the project, and a search func-
tionality to query the curated antimicrobial combinations
(Figure 3). The functional view of the network provides
several filters to navigate network contents and enables theT
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Figure 2. Historical evolution on the publication of AMP-drug combinations. Each row of columns represents data on a different microorganism
throughout time, namely (A) the number of publications identified as relevant and (B) the number of AMP-drug combinations reported.
Table 4. The top three most annotated AMP, drugs and organism strains in the database
Microorganism AMP Drug Strain
P. aeruginosa Colistin (10.9%) Novobiocin (16.9%) Clinical isolates (53.8%)
Polymyxin B (6.69%) Ciprofloxacin (6.38%) ATCC 27853 (17.6%)
Polymyxin B nonapeptide (5.78%) Imipenem (4.41%) PAO1 (13.3%)
S. aureus Nisin (12.0%) Vancomycin (8.43%) Clinical isolates (20.1%)
Lactoferricin B (10.0%) Lysostaphin (4.82%) ATCC 25923 (16.8%)
CA-MA (3.73%) Ciprofloxacin (4.82%) ATCC 43300 (12.2%)
E. coli Nisin (5.95%) NaCl (6.52%) ATCC 25922 (37.3%)
Lactoferricin B (4.76%) Lysozyme (5.22%) Clinical isolates (11.8%)
LL-37 (4.46%) Lactoferrin (3.48%) O157:H7 (7.14%)
L. monocytogenes Nisin (68.2%) NaCl (6.52%) Scott A (24.0%)
Pediocin PA-1 (4.55%) LPS (6.52%) ATCC 7644 (9.33%)
Colistin (4.55%) EDTA (6.52%) ATCC 19113 (4.00%)
C. albicans Lactoferricin B (11.2%) Caspofungin (14.6%) SC5314 (15.6%)
Colistin (8.16%) NaCl (10.4%) Clinical isolates (15.6%)
Polymyxin B (7.14%) Fluconazole (9.38%) ATCC 90028 (14.1%)
Note: The percentage is relative to the total number of annotations for the respective entity class.
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discovery of indirect associations within the network and
among networks.
Users can explore particular antimicrobial combin-
ations or look into all the antimicrobial combinations for
one or all organisms. The combinations are displayed as a
non-oriented graph. Nodes represent the antimicrobial
agents, such that hexagon nodes stand for drugs and circu-
lar nodes stand for AMP. Nodes are also coloured accord-
ing to their network connectivity, i.e. red if the node is
connected to <25% of the edges, yellow if the node is con-
nected to 25–50% of the edges, and green if it is connected
to >50% of the edges in the database.
Each node provides details on the represented anti-
microbial agent, such as alternative names, chemical activ-
ity, cross-links to chemical and other external sources.
Moreover, the user may access the documents that sup-
ported the inclusion of the antimicrobial agent in the
network, both the original PubMed record and the curated
abstract containing the expert revised annotations.
Likewise, each edge describes the nature of the docu-
mented combination and available susceptibility data.
Once again, the user may access the documents that sup-
ported the inclusion of the antimicrobial agent in the
graph.
Network visualization is complemented by topological
statistics and network details, listed below the graph
viewer. Networks can be downloaded as PNG images or in
comma separated value format.
Case study: AMP-drug combination network for
S. Aureus
The discussion of the AMP-drug combination network for
S. aureus is used here as case study to exemplify the
Figure 3. Snapshot of the AMP-drug combination Web search interface. The search page (1) allows for several search criteria. Search results are rep-
resented in a network structure (2) that displays the selected nodes (blue coloured), their immediate neighbours and, if applicable, the intermediary
nodes that connect the selected nodes. Further details on nodes (3) and edges (4) are provided in additional tables and page views. In particular, the
user may always access the available evidences supporting a given antimicrobial combination (5) and all documents referring to a given AMP/drug
(6).
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exploration of our database. This network contains 224
AMP and drugs and a total of 462 experimentally vali-
dated combinations (Figure 4). The network is dominated
by a small number of highly connected nodes. In particu-
lar, the AMP nisin and lactoferricin B and the antibiotic
vancomycin are the most connected nodes (Figures 4 and
5), with degrees of 61, 51 and 35, respectively.
Most of the described combinations for S. aureus are of
type synergic (>200 combinations) or additive (>100 com-
binations). The average connectivity of this network is
3.46, i.e. each antimicrobial agent is in average connected
to three other antimicrobial agents, and the characteristic
path length is 4 (Figure 5).
Discovering and visualizing indirect associations
The term direct association refers to antimicrobial agent
combinations that have been experimentally tested and are
documented in at least one scientific publication.
Conversely, we use the term indirect association to denote
two scenarios: the first refers to antimicrobial agents that
potentially have the same mechanism of action given their
coincident combinations (both in the agents used and the
type of combinations) (Figure 6A); the second refers to
antimicrobial agent combinations that have not yet been
tested but present some potential considering that the indi-
vidual agents are connected through combinations with
other antimicrobial agents (Figure 6B).
The discovery of indirect associations is triggered when
the user points two antimicrobial agents. The system dis-
plays the sub-graph representing either the direct linking of
the two agents, including all the combinations documented
for both agents; or, the shortest path between them, includ-
ing intermediary agents and all the combinations docu-
mented for each agents. In both directly and indirectly
associated concepts views, users can browse underlying
documents by clicking on edges or nodes.
Figure 7 shows indirect associations between the anti-
microbial agents ciprofloxacin and rifampicin in the S. aur-
eus network. The selected drugs are interconnected by 5
‘intermediary’ agents (the AMP P6, P9, P12, P15 and P18),
with no record in the database of the two drugs being
tested together. In particular, these 5 combinations of
ciprofloxacin with P6, P9, P12, P15 and P18 were docu-
mented as additive whereas 3 of these combinations of ri-
fampicin were documented as additive and the other 2
Figure 4. Network showing the AMP combinations tested against S. aureus. The size of the nodes correlates directly with its degree of connectivity.
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were documented as indifferent (a closely related type of
combination to additive).
Both antibiotics have an intracellular action. Notably,
their mechanism of action consists in the inhibition of
nucleic acid enzymes, with ciprofloxacin inhibiting DNA
gyrase and topoisomerase IV (45) and rifampicin inhibiting
RNA polymerase (46).Given the similarity of the mechan-
isms of action of the two drugs and the combinations that
Figure 5. Details on the AMP-drug combinations tested against S. aureus. General network statistics (A) are detailed in terms of the distribution of
combinations by type (B), the identification of the highest degree nodes (C), the distribution of shortest path length (D), and a snapshot of the heat
map describing the distribution of all AMP–drug combinations in the database (E).
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they have in common, it is possible to identify promising
new combinations (Figure 7). For example, the AMP nisin,
CA-MA and indolicidin have between 3 and 6 reported
combinations with ciprofloxacin, all with synergic and
additive outcomes. So, it could be of interest to test these
same AMP with rifampicin in the expectation of obtain-
ing similar positive results (i.e. synergic or additive
combinations).
Discovering and visualizing multiple target
combinations
The visualization of AMP combinations across multiple or-
ganisms is another supported analysis with multiple appli-
cations. Cellular wall and membrane features, which are
usually used to divide bacteria into Gram-positive or
Gram-negative groups, are known to influence the effect-
iveness of the antimicrobial agents. Multi-organism
visualization for Gram-positive bacteria, e.g. may allow
the identification of combinations that are effective across
the Gram-positive bacteria analysed and that could be
promising candidates for testing in other organisms of the
same group.
Another possibility is the discovery of effective combin-
ations for two or more organisms that are co-infectious
(meaning that they appear together in infections). For ex-
ample, P. aeruginosa and S. aureus are found together in
many biofilm related infections, such as cystic fibrosis
pneumonia, catheter-related infections, diabetic foot ulcers
and other wounds (47). The inspection of the intersection
network of tested combinations for these two organ-
isms may expand our view of current research (Figure 8).
Additionally, by using indirect association analysis (Figure
6) researchers may find combinations, previously un-
tested, and with antimicrobial potential against both
pathogens.
Figure 6. Analysis of indirect associations between antimicrobial agents. (A) inference of possible similar mechanisms of action between antimicro-
bial agents 1 and 2; (B) inference of untested promising combination between antimicrobial agents 1 and 3. Circle shapes refer to antimicrobial
agents and diamond shapes refer to the type of combinations (A, antagonism; S, synergy).
Figure 7. Visualization of indirect associations between ciprofloxacin and rifampicin for S. aureus experiments.
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Conclusions
Antimicrobial therapy is being challenged by the ever
increasing number of drug resistant organisms, which are
rendering most of the conventional drugs unsuccessful.
The proposed semi-automated workflow enabled the con-
struction and sustains the update of a new database on ex-
perimentally tested antimicrobial agent combinations, with
focus on AMP, in order to facilitate the design of more ef-
fective antimicrobial treatments. Notably, one of the
unique features of our system lies in its capability to iden-
tify indirect associations among antimicrobial agents and
propose new combinations to be tested.
This workflow integrates semantic analysis of text to
identify key information components from biomedical sci-
entific documents, which are then stored in a structured
knowledge base over which biomedical queries are pro-
cessed. Annotation is done in a machine-readable format
that allows for the semi-automated curation and display of
antimicrobial annotations. The semantic network repre-
sentation highlights the role of individual antimicrobial
agents in various contexts, within and across organisms.
Specifically, the query processing module allows users to
formulate queries in a guided way at different levels of spe-
cificity, such as by organism, antimicrobial agent, and
combination effect.
The effort to fully curate new pathogens is considered
acceptable. We have a consolidated set of annotation
guidelines and the practical and continuous use of semi-
automated data pipeline enables the refinement of the
automated modules. Most notably, when starting the cur-
ation of a new pathogen, experts provide insights into the
suitably of the PubMed queries in use and document rele-
vance predictions. Literature about a given pathogen, i.e.
the textual contents of the documents, may be sufficiently
different to urge for query refactoring and/or model
retraining.
In the near future, the analysis of curated combinations
for multiple organisms will be extended so that it will be pos-
sible to calculate the union, intersection or difference among
networks. Likewise, we are investigating the use of deep
learning approaches to accelerate manual curation steps.
Currently, our workflow is using established methodologies
from information retrieval, but deep learning alternatives
may be advantageous to improve the generalization ability of
the classifier in both local and global scopes.
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